Intravenous Methylene blue
Phase 3
Intravenous Methylene blue is one of 57 therapeutic programs targeting Colorectal Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Camptosar
PfizerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Tecentriq
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
Balstilimab
AAgenus Inc.
Phase 3
5-Fu
TToray Industries, Inc
Phase 3
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Intravenous Methylene blue
CChinese University of Hong Kong
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Intravenous Methylene blue. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- CChinese University of Hong Kong